A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
Latest Information Update: 22 Sep 2024
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms EQUATOR
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 01 Mar 2022 Results evaluating the short- and long-term effects of brexpiprazole on patient functioning in schizophrenia using post hoc analysis of short and long term studies published in the Journal of Clinical Psychiatry
- 31 Jul 2018 According to a Lundbeck A/S media release, the European Commission has approved Rxulti (brexpiprazole) for the treatment of schizophrenia in adults.
- 01 Jun 2018 According to a Lundbeck A/S media release, Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion on Rxulti (brexpiprazole) for the treatment of schizophrenia in adults. A final decision from the European Commission is expected within 67 days.